Maravai LifeSciences Holdings, Inc. (MRVI)

Market Cap	527.11M
Revenue (ttm)	259.19M
Net Income (ttm)	-144.85M
Shares Out	254.64M
EPS (ttm)	-1.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,726,137
Open	2.085
Previous Close	2.120
Day's Range	2.060 - 2.145
52-Week Range	1.665 - 11.560
Beta	0.19
Analysts	Hold
Price Target	6.54 (+215.94%)
Earnings Date	May 12, 2025

About MRVI

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 20, 2020
• Employees: 570
• Stock Exchange: NASDAQ
• Ticker Symbol: MRVI
• Website: https://www.maravai.com

Financial Performance

In 2024, MRVI's revenue was $259.19 million, a decrease of -10.30% compared to the previous year's $288.95 million. Losses were -$144.85 million, 21.7% more than in 2023.

Analyst Forecast

According to 9 analysts, the average rating for MRVI stock is "Hold." The 12-month stock price forecast is $6.54, which is an increase of 215.94% from the latest price.

Price Target

$6.54

(215.94% upside)

Analyst Consensus: Hold